Last Updated 31 May 2013
The Turkish pharmaceutical
market is the 6th largest in Europe and the 16th largest in the world and
experienced rapid growth until 2011. A substantial increase in national
investment in healthcare and the creation of a universal health insurance
system have boosted demand for healthcare services, including prescription
drugs. However, a tough pricing and reimbursement environment and restrictions
on market access for new imported drugs present serious challenges for
multinational pharmaceutical companies (MNCs) interested in this emerging
market. New cost-containment measures unveiled in November 2011 and health technology assessment measures made
effective in February 2013 have added to the industry’s woes.
Market profile: Market access drivers; key opportunities and
challenges; analysis of more than 40 market parameters.
Economic outlook: Global, regional, and country growth rates,
Socioeconomic trends of 7
Middle East and Africa countries: Gross domestic product (GDP), nominal per capita gross national income (GNI).
Demographics of 7 Middle
East and Africa countries projected
to 2030: Population size; population growth rate; life
expectancy at birth; median age; percentage of population aged 65 or more;
percentage of population that is urban.
Healthcare investments of
7 Middle East and Africa countries: Healthcare
spending as percentage of GDP (2000-2010), healthcare spending by government
and private entities (2010); healthcare spending per capita (2000-2010).
Pharmaceutical markets (3
regions and 15 countries): Ranking
by size; market sizes; market growth; Turkish pharmaceutical market; growth
rates by volume and by sales; imported drug market share by volume and sales.
Healthcare system: Evolution of the Turkish healthcare system; impact of
the Health Transformation Program; actions taken to achieve universal health
insurance; reorganization of the Ministry of Health and its affiliates.
pharmaceuticals: Key laws, regulations, and decision makers;
requirements for marketing authorization; regulations for clinical trials and
pharmacovigilance; harmonization activities; GMP requirements and delays;
health technology assessment process; marketing authorization of imported,
generic, biosimilar, and orphan drugs; promotion and advertising regulations;
Intellectual property: Key decision makers; patent legislation; limitations
of Turkish data protection provisions.
Pharmaceutical pricing: Wholesaler and pharmacy margins; use of external
reference pricing as the starting point of price setting; reductions applied to
external reference prices for various categories of drugs; statutory discounts
levied by the social security system; recent changes to the pricing system;
currency exchange issues.
reimbursement: Data requirements and
procedures for admission to reimbursement; Turkish positive list; reimbursement
applications; and use of internal reference pricing.
Cost containment: National pharmaceutical budget and potential penalties for
overspending; price cuts; pharmacy discounts; prescribing restrictions;
out-of-pocket payments; use of generics; rational drug use.
Hospital pharmacy: Public hospitals; positive list of inpatient drugs;
tendering and contracts.
Outlook and implications
for the pharmaceutical industry: 11
key factors to appreciate when doing business in India.
Exhibits: 25 data-rich tables and figures.